New drugs such as Tarlige (Mirogabalin besylate by Daiichi Sankyo, Korea) used for the treatment of peripheral neuropathic pain and Smyraf (Peficitinib hydrobromide, Korea Astellas Pharmaceutical) for rheumatoid arthritis received domestic permission at the same time .

They are expected to compete with existing products of the same family.

The Ministry of Food and Drug Safety approved two new drugs on the 23rd, including 2.5mg, 5mg, 10mg, 15mg and 50mg of Tarlige, & 100mg of Smyraf. Both drugs were made by Japanese global pharmaceutical companies.

Tarlige has the efficacy(indication) of treatment of peripheral neuropathic pain. The dosage and dose is usually administered o